Brokers Issue Forecasts for ANI Pharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – HC Wainwright reduced their Q3 2024 earnings per share (EPS) estimates for shares of ANI Pharmaceuticals in a note issued to investors on Wednesday, June 26th. HC Wainwright analyst O. Livnat now anticipates that the specialty pharmaceutical company will post earnings of $0.75 per share for the quarter, down from their previous forecast of $0.82. HC Wainwright currently has a “Buy” rating and a $94.00 target price on the stock. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.37 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals’ FY2024 earnings at $3.34 EPS.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.16. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. The firm had revenue of $137.43 million during the quarter, compared to analysts’ expectations of $125.01 million.

Several other research analysts have also recently weighed in on ANIP. Truist Financial boosted their price objective on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Capital One Financial started coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 target price for the company. Finally, Guggenheim reiterated a “buy” rating and set a $77.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $82.75.

ANI Pharmaceuticals Stock Performance

ANIP stock opened at $63.68 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.95 and a quick ratio of 3.12. The company has a 50 day moving average price of $64.22 and a 200 day moving average price of $61.69. ANI Pharmaceuticals has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The stock has a market capitalization of $1.34 billion, a PE ratio of 39.80 and a beta of 0.81.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $67.25, for a total value of $1,345,000.00. Following the completion of the sale, the senior vice president now owns 253,226 shares in the company, valued at approximately $17,029,448.50. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $67.25, for a total value of $1,345,000.00. Following the completion of the sale, the senior vice president now owns 253,226 shares in the company, valued at approximately $17,029,448.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Muthusamy Shanmugam sold 7,414 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $66.33, for a total transaction of $491,770.62. Following the completion of the transaction, the chief operating officer now directly owns 825,206 shares of the company’s stock, valued at $54,735,913.98. The disclosure for this sale can be found here. In the last 90 days, insiders sold 176,688 shares of company stock worth $11,408,863. Insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Boston Partners acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth about $606,000. Hancock Whitney Corp acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth about $360,000. California State Teachers Retirement System boosted its stake in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock worth $1,118,000 after buying an additional 233 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth about $289,000. Finally, CANADA LIFE ASSURANCE Co boosted its stake in shares of ANI Pharmaceuticals by 7.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 13,036 shares of the specialty pharmaceutical company’s stock worth $900,000 after buying an additional 909 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.